Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Friday, Pfizer Inc PFE slashed its full-year earnings and revenue guidance, citing decreasing demand for its COVID-19 products. The company now expects 2023 sales of $58 billion-$61 billion, down ...

Why Pfizer stock fell Pfizer stock fell about 8% when the market opened on Dec. 13 in a knee-jerk reaction to forward-looking estimates that didn't align with Wall Street's predictions.

Despite Pfizer trailing behind the broader market over the past year, Wall Street analysts remain moderately bullish about the stock's potential.

Pfizer Inc. raised its profit expectations for the year, citing new cancer drugs, as it seeks to dig out of a Covid-related hole in sales.

PFIZER (PFE): Free Stock Analysis Report This article What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday? originally appeared on Benzinga.com ...

Pfizer raised the lower end of its full-year revenue guidance to $99.5 billion to $102 billion. Analysts surveyed by FactSet had forecast revenue of $99.7 billion.

Bourla expressed confidence in Pfizer’s ability to compete and succeed in the obesity market. Analysts projected the obesity drug market to reach $100 billion by the decade’s end.